Avantor, Inc. (NYSE:AVTR) Short Interest Update

Avantor, Inc. (NYSE:AVTR - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 29,570,000 shares, a growth of 20.6% from the December 15th total of 24,520,000 shares. Based on an average daily trading volume, of 5,720,000 shares, the days-to-cover ratio is presently 5.2 days.

Avantor Trading Down 1.9 %

Avantor stock traded down $0.43 during trading on Monday, hitting $22.14. The company's stock had a trading volume of 6,042,606 shares, compared to its average volume of 3,101,021. The stock's fifty day moving average is $21.45 and its 200 day moving average is $23.39. Avantor has a 1-year low of $19.59 and a 1-year high of $28.00. The stock has a market capitalization of $15.07 billion, a price-to-earnings ratio of 48.13, a P/E/G ratio of 3.42 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AVTR. Royal Bank of Canada reaffirmed an "outperform" rating and set a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Robert W. Baird decreased their price objective on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Wells Fargo & Company lowered their price objective on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Monday, October 28th. Barclays cut their target price on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Friday, October 25th. Finally, UBS Group reissued a "neutral" rating and set a $25.00 price objective (down from $29.00) on shares of Avantor in a research note on Friday. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Avantor by 99.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock worth $26,000 after buying an additional 625 shares during the last quarter. UMB Bank n.a. purchased a new stake in Avantor during the third quarter valued at about $49,000. Nisa Investment Advisors LLC increased its stake in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock worth $53,000 after acquiring an additional 835 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock worth $70,000 after purchasing an additional 1,285 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its stake in shares of Avantor by 278.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company's stock valued at $130,000 after purchasing an additional 3,700 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.